RegulatoryJun 4, 2026, 04:12 PM
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003
AI Summary
Quoin Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation to its QRX003 lotion (4%) for the treatment of Netherton Syndrome. This designation offers significant development incentives in Japan, including up to 10 years of market exclusivity upon approval. The company is advancing QRX003, with a pivotal Phase 3 study planned for the second half of 2026 and a potential NDA filing in 2027.
Key Highlights
- Japan's MHLW granted Orphan Drug Designation to Quoin's QRX003 lotion (4%) for Netherton Syndrome.
- The designation provides development incentives in Japan, including up to 10 years of market exclusivity.
- QRX003 has previously received Orphan Drug Designation from the U.S. FDA and European Medicines Agency.
- Quoin is preparing for a pivotal Phase 3 study of QRX003, expected to initiate in H2 2026.
- The company anticipates a potential NDA filing for QRX003 in 2027.
Price Impact
More from QNRX